$10B Market By 2022: Pharmacyclic's Piece Of It YCharts To date, first-line treatment has usually consisted of Roche's monoclonal antibody Rituxan (rituximab) – which is directed against the CD20 antigen found on Beta lymphocytes – combined with a multi-agent chemotherapy regimen, most often CHOP ... |
